rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    ATRC
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      AtriCure to Participate in the Piper Sandler 38th Annual Healthcare Conference
      Nov 17Yahoo FinanceATRC
      Stifel reiterates Buy rating on AtriCure stock after conference
      Nov 12Investing.comATRC
      AtriCure Board Member Sold $143K In Company Stock
      Nov 11BenzingaATRC
      AtriCure at UBS Global Healthcare Conference: growth broadens
      Nov 9Investing.comATRCUBS
      AtriCure: A New Quality Metric Could Put A Clip In Nearly Every Sternotomy (NASDAQ:ATRC)

      AtriCure expands beyond AF to all open-heart surgeries, with 2027 catalysts, strong profitability, and growth. Click for more on ATRC stock.

      Nov 8Seeking AlphaATRC
      Is AtriCure (ATRC) Fully Valued After Strong Results And Raised 2026 Guidance?
      Nov 5Yahoo FinanceATRC
      AtriCure stock hits 52-week high at $63.00
      Nov 4Investing.comATRC
      AtriCure Analysts Boost Their Forecasts After Better-Than-Expected Q3 Results
      Nov 4BenzingaATRC
      What AtriCure (ATRC) Said on Its Q3 Earnings Call
      Nov 4Yahoo FinanceATRC
      AtriCure earnings beat by $0.21, revenue topped estimates
      Nov 3Investing.comATRC
      AtriCure Q3 2026 Earnings Call Transcript
      Nov 3BenzingaATRC
      Compared to Estimates, AtriCure (ATRC) Q3 Earnings: A Look at Key Metrics
      Nov 3Yahoo FinanceATRC
      AtriCure (ATRC) Beats Q3 Earnings and Revenue Estimates

      AtriCure (ATRC) delivered earnings and revenue surprises of +1,600.00% and +2.11%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

      Nov 3Yahoo FinanceATRC
      AtriCure: Q3 Earnings Snapshot
      Nov 3Yahoo FinanceATRC
      AtriCure Reports Third Quarter 2026 Financial Results
      Nov 3Yahoo FinanceATRC
      AtriCure earnings up next: Can pain management sustain the rally?
      Nov 3Investing.comATRC
      AtriCure stock hits 52-week high at 61.71 USD
      Oct 27Investing.comATRC
      AtriCure to Participate at Upcoming Investor Conferences
      Oct 26Yahoo FinanceATRC
      Citizens raises AtriCure stock price target to $68 on pipeline
      Oct 21Investing.comATRC
      AtriCure to Announce Third Quarter 2026 Financial Results
      Oct 13Yahoo FinanceATRC
      AtriCure (ATRC) Stock Gets Fair Value Bump As Analysts Weigh Procedure Growth And Risks

      AtriCure’s fair value price target has shifted from about US$51.67 to about US$54.89, which reflects modest fine tuning in analyst models rather than a wholesale reset. Recent research ties these adjustments to how analysts balance new procedural drivers such as the STS Quality Metric and future BoX-NoAF POAF data against ongoing clinical and execution risks, as well as the tighter cluster of targets around the current valuation range. Read on to see how to track this evolving analyst...

      Oct 5Yahoo FinanceATRC
      Analysts Offer Insights on Healthcare Companies: Shattuck Labs (STTK) and Atricure (ATRC)

      Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.

      Oct 3The Globe and MailATRCSTTK
      Freedom Capital downgrades AtriCure stock rating to hold, raises price target to $57
      Oct 2Investing.comATRC
      AtriCure (ATRC) Stock Looks Rich Against Its Sales Base

      AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the business is actually generating. The share price has gained 73.5% over the past year, which puts added weight on whether the current valuation can be explained by its sales base. The company’s focus on cardiac surgical devices means future growth in procedure...

      Sep 25Yahoo FinanceATRC
      Why AtriCure (ATRC) Is Back In The Spotlight

      AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day share price return of 24.84% and a 90-day share price return of 101.36%. This feeds into a year-to-date share price gain of 54.75% and a 1-year total shareholder return of 73.48%, even though the 5-year total shareholder return is down 12.62%. Spot fresh...

      Sep 25Yahoo FinanceATRC
      AtriCure CTO Salvatore Privitera sells $271,140 in stock
      Sep 25Investing.comATRC
      Atricure Insider Sold Shares Worth $271,140, According to a Recent SEC Filing

      Salvatore Privitera, Chief Technical Officer, on September 23, 2026, sold 4,519 shares in Atricure (

      Sep 24Yahoo FinanceATRC
      AtriCure stock hits 52-week high at $59.91
      Sep 23Investing.comATRC
      Stifel reiterates Buy rating on AtriCure stock, $65 target
      Sep 17Investing.comATRC
      Insider Selling: Regina E Groves Unloads $288K Of AtriCure Stock
      Sep 15BenzingaATRC
      AtriCure director Regina Groves sells $288,070 of stock
      Sep 14Investing.comATRC
      AtriCure stock hits 52-week high at 55.83 USD
      Sep 14Investing.comATRC
      Is AtriCure (ATRC) Stock Outpacing Its Medical Peers This Year?
      Sep 14Yahoo FinanceATRC
      AtriCure CTO Sells 3,657 Shares | The Motley Fool

      Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.

      Sep 13The Motley FoolATRC
      AtriCure CTO Sells 3,657 Shares

      Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.

      Sep 12The Globe and MailATRC
      Do Options Traders Know Something About AtriCure Stock We Don't?
      Sep 10Yahoo FinanceATRC
      AtriCure CTO Salvatore Privitera sells $201,135 in shares
      Sep 10Investing.comATRC
      AtriCure, Inc. (ATRC) Hit a 52 Week High, Can the Run Continue?

      AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

      Sep 9Yahoo FinanceATRC
      AtriCure at Wells Fargo conference: growth and margins run ahead
      Sep 8Investing.comATRCWFC
      Atricure CTO Salvatore Privitera sells $407,557 in stock
      Sep 4Investing.comATRC
      Atricure Insider Sold Shares Worth $407,558, According to a Recent SEC Filing

      Privitera Salvatore, Chief Technical Officer, on September 02, 2026, sold 7,763 shares in Atricure (

      Sep 4Yahoo FinanceATRC
      Atricure stock hits 52-week high at $50.00
      Sep 2Investing.comATRC
      Needham raises AtriCure stock price target on trial outlook
      Sep 2Investing.comATRC
      Needham Raises Price Target on AtriCure to $64 From $45, Keeps Buy Rating

      AtriCure (ATRC) has an average rating of buy and mean price target of $51.67, according to analysts

      Sep 2Yahoo FinanceATRC
      Piper Sandler raises AtriCure stock price target on quality measure
      Aug 27Investing.comATRC
      Is AtriCure (ATRC) Outperforming Other Medical Stocks This Year?

      Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

      Aug 27Yahoo FinanceATRC
      Karl S Dahlquist Implements A Sell Strategy: Offloads $458K In AtriCure Stock
      Aug 26BenzingaATRC
      Atrial Fibrillation Treatment Devices Market Trends and Forecast, 2035 | Includes Profiles of Abbott, AtriCure, Boston Scientific, Johnson & Johnson, and Medtronic

      Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursement and regulatory support offer further growth. Atrial Fibrillation Treatment Devices Market Atrial Fibrillation Treatment Devices Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Devices Market by Type of Device, Type of Technology, End

      Aug 26Yahoo FinanceATRCBSXJNJMDT
      AtriCure chief legal officer sells $458,099 in stock
      Aug 26Investing.comATRC
      AtriCure to Participate in the 2026 Wells Fargo Health Care Conference

      MASON, Ohio, August 25, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

      Aug 25Yahoo FinanceATRC

      This is the newest page. Registered accounts read further back.